CD274 and urinary bladder cancer: To explore the potential effect and mechanism of m6A methylation on immunotherapy for bladder cancer, we obtained data for the IMvigor210 cohort, which is an open-label, multicenter, single-arm phase II clinical study to evaluate the safety and efficacy of Tecentriq, an anti-PD-L1 agent, in patients with advanced urothelial cancer (Supplementary Table 4).